Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

• Published in: FEBS letters Vol. 584; no. 12; pp. 2670 - 2680
• Main Authors: Löfblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J., Ståhl, S., Frejd, F.Y.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 18.06.2010
• Subjects: Affibody molecule; Affinity Labels - chemistry; Affinity Labels - therapeutic use; Alternative scaffold; Amino Acid Sequence; Animals; Bioengineering; Biotechnology; Bioteknik; Biotherapy; Combinatorial protein engineering; Humans; MEDICIN; MEDICINE; Molecular Imaging; Molecular Sequence Data; Phage display; Protein Engineering; Receptor, ErbB-2 - metabolism; Recombinant Proteins - chemistry; Recombinant Proteins - therapeutic use; TECHNOLOGY; TEKNIKVETENSKAP; Terminology as Topic; Molecular imaging; Combinatorial protein engineering; Phage display; Biotherapy; Affibody molecule; Alternative scaffold
• ISSN: 0014-5793; 1873-3468; 1873-3468
• DOI: 10.1016/j.febslet.2010.04.014

Affibody molecules are a class of engineered affinity proteins with proven potential for therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5 kDa) single domain proteins that can be isolated for high affinity and specificity to any given protein target. Fifteen years after its discovery, the Affibody technology is gaining use in many groups as a tool for creating molecular specificity wherever a small, engineering compatible tool is warranted. Here we summarize recent results using this technology, propose an Affibody nomenclature and give an overview of different HER2-specific Affibody molecules. Cumulative evidence suggests that the three helical scaffold domain used as basis for these molecules is highly suited to create a molecular affinity handle for vastly different applications.